DGAP-News: A*STAR and Cytos extend Influenza Vaccine Collaboration to Supply of Clinical Trial Material
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Alliance
A*STAR and Cytos extend Influenza Vaccine Collaboration to Supply of
Clinical Trial Material
16.12.2010 / 02:00
---------------------------------------------------------------------
Cytos Biotechnology will receive fees for the Development, Manufacture and
Supply of GMP-grade Influenza Vaccine Candidate
1. Schlieren (Zurich), Switzerland&Singapore, December 16, 2010 -
Switzerland's Cytos Biotechnology Ltd (SIX:CYTN) and Singapore's Agency
for Science, Technology and Research (A*STAR) jointly announced today
the extension of their existing collaboration for the development of a
virus-like particle (VLP) based Influenza vaccine. Under this revised
agreement, A*STAR will engage Cytos to develop, manufacture, and supply
A*STAR with a Good Manufacturing Practice (GMP)-grade investigational
vaccine candidate for a human proof-of-concept study in Singapore.
2. This extension follows an earlier Collaborative Research, Development
and Commercialisation Agreement, signed by Cytos and A*STAR on 15th
July 2010, to perform research, development and commercialization of a
VLP vaccine to manage influenza infections. The objective of this
agreement is to establish an independent supply of influenza vaccine
for ASEAN and to extend Cytos' R&D pipeline. Cytos holds the worldwide,
sub-licensable rights to further develop the vaccine, while A*STAR
subsidiaries would earn a royalty on worldwide sales of influenza
vaccine products developed under this agreement.
3. Frank Hennecke, PhD, Executive Vice President Product Development at
Cytos Biotechnology commented: 'I am very pleased we can contribute our
GMP technology and process know-how in the VLP field to this
collaboration. Cytos' continuing ability to supply its partners with
clinical trial material is a key asset to rapidly move preclinical
programs into the clinic.'
4. 'The extension of our collaboration for human proof-of-concept studies
is a major step in bringing our research findings from the laboratory
to the clinics where they can benefit patients. It also furthers
A*STAR's close relationship with our industry partners,' said Prof Alex
Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics
Centre (ETC). Added Prof Paola Castagnoli, Scientific Director of
A*STAR's Singapore Immunology Network (SIgN), 'We are confident that
with the combined knowledge base of Singapore's research institutes and
the capabilities of industry, we will produce a valuable and
cost-effective healthcare solution for Singapore and beyond.'
For further information about the Immunodrug(TM) agreement between A*STAR
and Cytos Biotechnology in the Influenza field, see Cytos' and A*STAR's
joint press release dated July 15, 2010.
For media queries, please contact:
Cytos Biotechnology Ltd
Wolfgang A. Renner, PhD
Chief Executive Officer
DID: +41 44 733 47 03
Email: wolfgang.renner(at)cytos.com
Agency for Science, Technology and Research (A*STAR)
Ms Adela Foo
Senior Officer, Corporate Communications
DID: +65 6826 6218
Email: adela_foo(at)a-star.edu.sg
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which five are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 81 full-time equivalents.
Cytos Biotechnology Ltd is listed on the main segment at the SIX Swiss
Exchange (SIX:CYTN).
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is the lead agency
for fostering world-class scientific research and talent for a vibrant
knowledge-based and innovation-driven Singapore. A*STAR oversees 14
biomedical sciences and physical sciences and engineering research
institutes, and nine consortia¢res, located in Biopolis and
Fusionopolis as well as their immediate vicinity.
A*STAR supports Singapore's key economic clusters by providing
intellectual, human and industrial capital to its partners in industry. It
also supports extramural research in the universities, hospitals, research
centres, and with other local and international partners.
For more information about A*STAR, please visit www.a-star.edu.sg.
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'will', 'can', 'designed', 'intended' or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments. This document does not constitute an offer
or invitation to subscribe or purchase any securities of Cytos
Biotechnology Ltd.
End of Corporate News
16.12.2010 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the
capital market and press releases.
The EquityStory Group distributes authentic and real-time financial
news for over 1'300 listed companies.
The Swiss news archive can be found at
http://www.equitystory.ch/nachrichten
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.comISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Regulierter Markt in SIX; Freiverkehr in
Berlin, München, Stuttgart; Open Market in
Frankfurt
End of News EquityStory AG News-Service
---------------------------------------------------------------------
106531 16.12.2010
Datum: 16.12.2010 - 02:00 Uhr
Sprache: Deutsch
News-ID 32870
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 458 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: A*STAR and Cytos extend Influenza Vaccine Collaboration to Supply of Clinical Trial Material"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
